Document Detail


An emerging role for calcium sensitisation in the treatment of heart failure.
MedLine Citation:
PMID:  16004594     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Heart failure occurs in 2 - 3% of the adult population in the developed world. With decompensation of cardiac function, haemodynamic stability can be achieved by using intravenous vasodilators, diuretics and inotropes. Unlike traditional inotropes, Ca2+ sensitisers enhance cardiac function without significantly increasing cardiac oxygen consumption, promoting arrhythmia or impairing lusitropy. The most promising drug in this new class is levosimendan, which has a unique dual mechanism; it enhances cardiac output through a Ca(2+)-dependent stabilisation of cardiac myofilaments and exhibits vasodilatory effects by opening ATP-dependent K(+) channels. Clinical trials have demonstrated the beneficial haemodynamic effects of levosimendan, and prospective trials are currently underway to confirm its potential benefits on long-term prognosis. Updated guidelines from the European Society of Cardiology advise on how to incorporate levosimendan into care for patients who have acute heart failure.
Authors:
Leif Erhardt
Related Documents :
17187454 - Carvedilol: use in chronic heart failure.
25456414 - Prospective, multi-center evaluation of a silicon carbide coated cobalt chromium bare m...
15631334 - Heart failure in patients with chronic kidney disease.
7473524 - Ace inhibitors for the prevention and treatment of heart failure: why are they 'under-u...
6207954 - Incidence of the coexistence of left ventricular false tendons and premature ventricula...
21877874 - Impact of a territorial st-segment elevation myocardial infarction network on prognosis...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  14     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-07-11     Completed Date:  2006-04-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  659-70     Citation Subset:  IM    
Affiliation:
Lund University, Malmö University Hospital, 205 02 Malmö, Sweden. Leif.Erhardt@medforsk.mas.lUSe
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Calcium Signaling / drug effects*,  physiology
Clinical Trials as Topic / trends
Drugs, Investigational / chemistry,  pharmacology,  therapeutic use*
Heart Failure / drug therapy*,  metabolism
Humans
Hydrazones / chemistry,  pharmacology,  therapeutic use
Myocytes, Cardiac / drug effects,  physiology
Pyridazines / chemistry,  pharmacology,  therapeutic use
Chemical
Reg. No./Substance:
0/Drugs, Investigational; 0/Hydrazones; 0/Pyridazines; 131741-08-7/simendan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Novel therapeutics in adult malignant brain gliomas.
Next Document:  Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therape...